A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 147 participants.
Also called NCT01258907
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 147 participants
- Sponsor
- Registry
-
NCT01258907
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT01258907. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2012-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
- Condition
- Atherosclerosis
- Intervention (Drug)
- MLDL1278A
- Intervention (Drug)
- MLDL1278A
- Intervention (Drug)
- placebo
- Intervention (Drug)
- statin, stable dose
- Lead sponsor
- Genentech, Inc.
- Collaborator
- BioInvent International AB
Record details
- Record id
cardio:ct-nct01258907- Content hash
fc405eed8d5ee683cb52677a8150916de1b78e11175ee0e9916e96583f1c3487